Regencell Bioscience Holdings Ltd (RGC)

$4.59

-0.11

(-2.34%)▲

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Regencell Bioscience Holdings Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, -2.34B → -2.34B (in $), with an average decrease of 0.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -1.32K → -2.64M (in $), with an average decrease of 199899.4% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 51.6% return, outperforming this stock by 131.2%

Performance

  • $4.36
    $4.59
    $4.59
    downward going graph

    5.01%

    Downside

    Day's Volatility :5.01%

    Upside

    0.0%

    downward going graph
  • $3.16
    $30.49
    $4.59
    downward going graph

    31.15%

    Downside

    52 Weeks Volatility :89.64%

    Upside

    84.95%

    downward going graph

Returns

PeriodRegencell Bioscience Holdings LtdIndex (Russel 2000)
3 Months
-23.5%
0.0%
6 Months
-56.28%
0.0%
1 Year
-83.29%
0.0%
3 Years
-56.29%
-22.6%

Highlights

Market Capitalization
61.2M
Book Value
$0.92
Earnings Per Share (EPS)
-0.45
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-25.59%
Return On Equity TTM
-41.71%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-6.0M
Diluted Eps TTM
-0.45
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Technicals Summary

Sell

Neutral

Buy

Regencell Bioscience Holdings Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Ltd
-23.24%
-56.28%
-83.29%
-56.29%
-56.29%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-1.26%
20.07%
49.07%
48.24%
66.16%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
2.79%
0.0%
2.67%
14.3%
14.3%
Zoetis Inc.
Zoetis Inc.
3.87%
-5.35%
0.73%
-1.62%
59.42%
Viatris Inc.
Viatris Inc.
-10.49%
9.3%
13.4%
-31.25%
-35.25%
Catalent, Inc.
Catalent, Inc.
-3.71%
35.8%
43.6%
-46.34%
16.03%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Ltd
NA
NA
NA
0.0
-0.42
-0.26
NA
0.92
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
36.8
36.8
0.44
4.07
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.13
28.13
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
32.67
32.67
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.05
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.25
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Ltd
NA
$61.2M
-56.29%
NA
0.0%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.6B
66.16%
36.8
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.5B
14.3%
28.13
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$77.4B
59.42%
32.67
27.38%
Viatris Inc.
Viatris Inc.
Hold
$12.6B
-35.25%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$9.7B
16.03%
211.02
-28.44%

Institutional Holdings

  • UBS Group AG

    0.01%

Company Information

we are an early-stage bioscience company that focuses on research, development and commercialization of tcm for the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder (“adhd”), autism spectrum disorder (“asd”) in infectious diseases such as covid-19. our goal is to improve the lives of adhd, asd and covid patients, their families and caregivers and become a market leader for the best tcm treatment globally.

Organization
Regencell Bioscience Holdings Ltd
Employees
12
CEO
Mr. Yat-Gai Au
Industry
Miscellaneous

Discover More

FAQs